Instruction 1(b).

FORM 4

Check this box if no longer subject to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP
STATEMENT	OF CHANGES	IN DENEFICIAL	OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Section 16. Form 4 or Form 5 obligations may continue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Pernock David			E.A	2. Issuer Name and Ticker or Trading Symbol EAGLE PHARMACEUTICALS, INC. [EGRX]							(Che	eck all applic	r 10% O		on(s) to Iss 10% Ov Other (s	ner			
(Last)	(F	irst)	(Middle)											2	below)	(give title		below)	poony
EAGLE PHARMACEUTICALS, INC. 50 TICE BLVD., SUITE 315				3. Date of Earliest Transaction (Month/Day/Year) 01/04/2017								Pres.	& Chief (Com	m. Office	:			
(Street)				4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
WOODC	LIFF N	T	07677												,	led by One	Repo	rting Perso	1
LAKE	10	3	07077												Form fi Person	led by More	than	One Repor	ting
(City)	(S	tate)	(Zip)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			Execution Date		Date,	Transaction Disposed Code (Instr. 5)		ities Acquired (A) o d Of (D) (Instr. 3, 4 a		A) or , 4 and		es Formally (D) (Following (I) (I		Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership				
							Code	v	Amount	(A) or (D)		Price	Reported Transact (Instr. 3 a	ansaction(s) str. 3 and 4)			(Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, ecurity or Exercise (Month/Day/Year) if any		ate, Ti	Transaction Code (Instr.		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				c	ode	v	(A)	(D)	Date Exercisable		Expiration Date	Title	or Nu of	ımber					
Stock Option (right to buy)	\$84.92	01/04/2017			A		90,000		(1)	0	1/03/2027	Commo Stock	90	0,000	\$0.00	90,000		D	

Explanation of Responses:

1. The option vests over a period of four years, with 25% of the shares underlying the option vesting on January 4, 2018, the first anniversary of the date of grant, and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

Remarks:

/s/ Scott Tarriff, Attorney-in-

Fact

01/06/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.